icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
Back grey_arrow_rt.gif
 
 
 
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS
 
 
  CROI 2020 March 9
Reported by Jules Levin
 
Chloe Orkin,1Shinichi Oka,2Patrick Philibert,3Cynthia Brinson,4Ayesha Bassa,5Denis Gusev,6Olaf Degen,7Juan Gonzalez Garcia,8Ronald D'Amico,9David Dorey,10Sandy Griffith,9David A. Margolis,9Marty St. Clair,9Peter Williams,11William R. Spreen9 1Queen Mary University, London, UK; 2National Center for Global Health and Medicine, Tokyo, Japan; 3Hopital Européen, Marseille, France; 4Central Texas Clinical Research, Austin, TX, USA; 5Mzansi Ethical Research Centre, Middelburg, South Africa;6State Medical Center for the Prevention and Control of AIDS and Infectious Diseases, St. Petersburg, Russia; 7University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 8Hospital Universitario La Paz, Madrid, Spain; 9ViiV Healthcare, Research Triangle Park, NC, USA; 10GlaxoSmithKline, Mississauga, ON, Canada; 11Janssen Research & Development, Beerse, Belgium

0310201

0310202

0310203

0310204

0310205

0310206